We have read with great interest the letter of the European Task Force on Atopic Dermatitis (ETFAD) on SARS-CoV-2-infection and atopic dermatitis published in JEADV (March 2020)1 in which the authors state: "Targeted treatment selectively interfering with type-2 inflammation such as dupilumab is not considered to increase the risk for viral infections and might thus be preferred …in a situation such as COVID-19 pandemic".1.
SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab
Caroppo, Francesca;Biolo, Giulia;Belloni Fortina, Anna
2020
Abstract
We have read with great interest the letter of the European Task Force on Atopic Dermatitis (ETFAD) on SARS-CoV-2-infection and atopic dermatitis published in JEADV (March 2020)1 in which the authors state: "Targeted treatment selectively interfering with type-2 inflammation such as dupilumab is not considered to increase the risk for viral infections and might thus be preferred …in a situation such as COVID-19 pandemic".1.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
